Literature DB >> 16633710

Infliximab in Takayasu arteritis: a safe alternative?

Zaharenia Th Karageorgaki1, Clio P Mavragani, Matthilde A Papathanasiou, Fotini N Skopouli.   

Abstract

OBJECTIVE: To test the efficacy of Infliximab, a chimeric monoclonal antibody against TNF-alpha, in the treatment of Takayasu arteritis.
MATERIALS AND METHODS: We used infliximab at an initial dose of 3 mg/kg i.v. at weeks 0, 2, 6, and 8 thereafter in combination with methotrexate or azathioprine, to treat four patients with Takayasu arteritis.
RESULTS: Three out of four patients responded to infliximab treatment, while two of them retained the response during a two-year follow up. A higher dose regimen (5 mg/kg), however, was eventually warranted for two of the responders. No major side effects were noted.
CONCLUSIONS: Infliximab might be an effective and safe alternative for patients with Takayasu arteritis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16633710     DOI: 10.1007/s10067-006-0227-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  18 in total

1.  Treatment of longstanding active giant cell arteritis with infliximab: report of four cases.

Authors:  F Cantini; L Niccoli; C Salvarani; A Padula; I Olivieri
Journal:  Arthritis Rheum       Date:  2001-12

2.  Infliximab Therapy for Patients With Active and Refractory Spondyloarthropathies at the Dose of 3 mg/kg: A 20-Month Open Treatment.

Authors:  E P Cherouvim; E Zintzaras; K A Boki; H M Moutsopoulos; M N Manoussakis
Journal:  J Clin Rheumatol       Date:  2004-08       Impact factor: 3.517

3.  Takayasu's arteritis and its therapy.

Authors:  J H Shelhamer; D J Volkman; J E Parrillo; T J Lawley; M R Johnston; A S Fauci
Journal:  Ann Intern Med       Date:  1985-07       Impact factor: 25.391

Review 4.  Infliximab: a new treatment for rheumatoid arthritis.

Authors:  P Emery
Journal:  Hosp Med       Date:  2001-03

Review 5.  Pathogenesis of Takayasu's arteritis.

Authors:  M Noris
Journal:  J Nephrol       Date:  2001 Nov-Dec       Impact factor: 3.902

6.  Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

Authors:  P P Sfikakis; P G Theodossiadis; C G Katsiari; P Kaklamanis; N N Markomichelakis
Journal:  Lancet       Date:  2001-07-28       Impact factor: 79.321

7.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

Authors:  J Braun; J Brandt; J Listing; A Zink; R Alten; W Golder; E Gromnica-Ihle; H Kellner; A Krause; M Schneider; H Sörensen; H Zeidler; W Thriene; J Sieper
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

8.  Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients.

Authors:  P Bartolucci; J Ramanoelina; P Cohen; A Mahr; P Godmer; C Le Hello; L Guillevin
Journal:  Rheumatology (Oxford)       Date:  2002-10       Impact factor: 7.580

9.  Takayasu arteritis.

Authors:  G S Kerr; C W Hallahan; J Giordano; R Y Leavitt; A S Fauci; M Rottem; G S Hoffman
Journal:  Ann Intern Med       Date:  1994-06-01       Impact factor: 25.391

10.  Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate.

Authors:  G S Hoffman; R Y Leavitt; G S Kerr; M Rottem; M C Sneller; A S Fauci
Journal:  Arthritis Rheum       Date:  1994-04
View more
  9 in total

Review 1.  Retrospective evaluation of 22 patients with Takayasu's arteritis.

Authors:  Nazife Sule Yasar Bilge; Timuçin Kaşifoğlu; Döndü U Cansu; Cengiz Korkmaz
Journal:  Rheumatol Int       Date:  2011-01-20       Impact factor: 2.631

2.  Novel strategy for the treatment of refractory vasculitis syndrome.

Authors:  Hidehiro Yamada
Journal:  Ann Vasc Dis       Date:  2013-02-15

Review 3.  Advances in the use of biologic agents for the treatment of systemic vasculitis.

Authors:  Sharon A Chung; Philip Seo
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

4.  Infliximab therapy in pediatric Takayasu's arteritis: report of two cases.

Authors:  Paola Sabrina Buonuomo; Claudia Bracaglia; Andrea Campana; Antonella Insalaco; Manuela Pardeo; Elisabetta Cortis; Alberto G Ugazio
Journal:  Rheumatol Int       Date:  2009-10-23       Impact factor: 2.631

5.  Biologic agents in systemic vasculitis.

Authors:  Charles F Henderson; Philip Seo
Journal:  Int J Clin Rheumtol       Date:  2011

Review 6.  The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.

Authors:  Mohammed Osman; Christian Pagnoux; Donna M Dryden; Dale Storie; Elaine Yacyshyn
Journal:  PLoS One       Date:  2014-12-17       Impact factor: 3.240

Review 7.  Informed consent and biological agents in rheumatology and internal medicine.

Authors:  Gabriele Mandarelli; Florenzo Iannone; Stefano Ferracuti; Ignazio Grattagliano; Marcello Benevento; Biagio Solarino; Davide Ferorelli; Roberto Catanesi
Journal:  Eur J Clin Invest       Date:  2022-05-18       Impact factor: 5.722

8.  Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study.

Authors:  Eun Hye Park; Eun Young Lee; Yun Jong Lee; You Jung Ha; Wan-Hee Yoo; Byoong Yong Choi; Jin Chul Paeng; Hoon Young Suh; Yeong Wook Song
Journal:  Rheumatol Int       Date:  2018-09-18       Impact factor: 2.631

9.  Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis.

Authors:  Ana F Águeda; Sara Monti; Raashid Ahmed Luqmani; Frank Buttgereit; Maria Cid; Bhaskar Dasgupta; Christian Dejaco; Alfred Mahr; Cristina Ponte; Carlo Salvarani; Wolfgang Schmidt; Bernhard Hellmich
Journal:  RMD Open       Date:  2019-09-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.